Biotech News

Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results

Medpace (MEDP)Medpace2026-06-25 13:46 ESTEarnings

Revenue of $708.5 million in the fourth quarter of 2025 increased 32.0% from revenue of $536.6 million for the comparable prior-year period, representing a backlog conversion rate of 23.6%. Net new business awards were $736.6 million in the fourth quarter of 2025, representing an increase of 39.1%

Open original release

Related news

Medpace

Medpace is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

Stock data

Close
Market cap
Exchange
NASDAQ
Sector
Biotechnology
Location
United States